Evidence map›Paper›PMID 27993663›Full record

ArticleThe Journal of urology2017

Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.

Huei-Ting Tsai, Ruth M Pfeiffer, George K Philips, Ana Barac, Alex Z Fu, David F Penson, Yingjun Zhou, Arnold L Potosky

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Cancer Evolvability Determines Therapy Outcomes.bioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Huei-Ting TsaiCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C.. Electronic address: hueiting.tsai@georgetown.edu.
Ruth M PfeifferNational Cancer Institute, National Institutes of Health, Bethesda, Maryland.
George K PhilipsDepartment of Medicine, Georgetown University Medical Center, Georgetown University, Washington, D.C.
Ana BaracDivision of Cardiology, MedStar Washington Hospital Center, Washington, D.C.
Alex Z FuCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C.
David F PensonDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Yingjun ZhouCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C.
Arnold L PotoskyCancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C.
National Cancer Institute · USVanderbilt University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
Outcomes of Prostate Cancer Androgen Deprivation TherapyR01CA142934 · NCI · GEORGETOWN UNIVERSITY · PI POTOSKY, ARNOLD L · 2010 to 2012
$1.8M
Cost-Effectiveness of Hormonal Therapy for Clinically Localized Prostate CancerRC1CA146238 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI POTOSKY, ARNOLD L, ULCICKAS YOOD, MARIANNE · 2009 to 2010
$997k
USE AND OUTCOMES OF INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCERR03CA167454 · NCI · GEORGETOWN UNIVERSITY · PI TSAI, HUEI-TING · 2012 to 2013
$151k
AHRQ HHS K01 HS022915Intramural NIH HHS Z99 CA999999NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA142934NCI NIH HHS R03 CA167454NCI NIH HHS RC1 CA146238
6 · The paper itself

Abstract

purposeRandomized trials have shown that intermittent androgen deprivation therapy for patients with advanced prostate cancer may improve sexual and physical functioning compared to continuous androgen deprivation therapy without compromising survival. To our knowledge it is unknown whether intermittent androgen deprivation therapy alters the risk of serious toxicities associated with continuous androgen deprivation therapy. MATERIALS AND

methodsWe performed a population based cohort study of 9,772 men 66 years old or older who were diagnosed with advanced prostate cancer from 2002 to 2011 and treated with androgen deprivation therapy. Intermittent androgen deprivation therapy was defined as a single 90-day interval between 2 androgen deprivation therapy sessions during which patients visited their physicians or underwent prostate specific antigen testing. Outcomes included acute myocardial infarction, stroke, heart failure, type 2 diabetes and fracture. We used Cox proportional hazard models to estimate the HRs of the comparative risk of serious toxicities between intermittent and continuous androgen deprivation therapy.

resultsA total of 2,113 (22%), 769 (9%) and 899 men (9%) had a new cardiovascular event, diabetes or fracture, respectively, within 5 years of starting androgen deprivation therapy. Compared to the continuous androgen deprivation therapy group, the intermittent therapy group was at lower risk for serious cardiovascular events (HR 0.64, 95% CI 0.53-0.77), particularly in reducing the risk of heart failure (HR 0.62, 95% CI 0.49-0.78) and fracture (HR 0.52, 95% CI 0.38-0.70, each p <0.0001).

conclusionsIntermittent androgen deprivation therapy was associated with a lower risk of heart failure and fracture compared to continuous androgen deprivation therapy. This raises toxicity concerns for continuous relative to intermittent therapy and suggests that intermittent androgen deprivation therapy may represent a safer therapeutic choice in elderly men with advanced prostate cancer.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCohort StudiesDrug Administration ScheduleHumansMaleProportional Hazards ModelsProstatic NeoplasmsRegistriesRisk AssessmentRisk FactorsAndrogen AntagonistsAntineoplastic Agents, Hormonalandrogen antagonistsantineoplastic agentsdrug related side effects and adverse reactionshormonalprostatic neoplasmsrisk

Identifiers

PMID27993663
PMCPMC5794210
OpenAlexW2562919405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.